Clinical Translation of Precision Medicine in a First Clinically & Biologically Defined Subgroup of Patients with Autism Spectrum Disorder

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1771143e105">Limited behavioral DSM-5 diagnostic criteria fails to acknowledge the significant heterogeneity present in neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), contributing to repeated clinical trial failures in the field. To address this challenge, STALICLA has developed a unique precision neuroscience data platform, Databased Endophenotyping Patient Identification (DEPI), that enables the identification of stratified patient subgroups and advances tailored treatment options for ASD. A first clinically and biologically defined subgroup of ASD patients, named ASD-Phen1, was clinically validated in 2 prospectives biosampling studies (Greenwood Genetic Center, Cincinnati Children’s Medical Center) with an observed incidence of 20-25% of the enrolled ASD population (Perez-Cano, et al. 2024). This subgroup was then biologically validated through multi-omics characterization (metabolic, metabolomic, transcriptomic) revealing specific molecular signatures for ASD-Phen1 patients that were found to be reversed by STALICLA's precision medicine STP1 (a combination of a PDE4/3 inhibitor (ibudilast) and an NKCC1 antagonist (bumetanide)). Ensuing STP1 Phase 1b in ASD-Phen1 established good safety-tolerability, strong target engagement signals (EEG), and superiority on recognized-clinical efficacy endpoints (ABC, SRS, NIH toolbox) as well as convincing PK/PD profile (Erickson, et al. 2024). <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e107"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e108"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e109"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e110"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e111"/>

Authors

Institutions

Publication Details

Published
2025-08-22
DOI
https://doi.org/10.58647/rexpo.25000120.v1
Primary Topic
Autism Spectrum Disorder Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Translation of Precision Medicine in a First Clinically & Biologically Defined Subgroup of Patients with Autism Spectrum Disorder

Laura Pérez‐Cano, Lynn Durham, Sara Azidane
1 links
Autism Spectrum Disorder Research
article

Clinical Translation of Precision Medicine in a First Clinically & Biologically Defined Subgroup of Patients with Autism Spectrum Disorder

Laura Pérez‐Cano, Lynn Durham, Sara Azidane
article en

Abstract

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1771143e105">Limited behavioral DSM-5 diagnostic criteria fails to acknowledge the significant heterogeneity present in neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), contributing to repeated clinical trial failures in the field. To address this challenge, STALICLA has developed a unique precision neuroscience data platform, Databased Endophenotyping Patient Identification (DEPI), that enables the identification of stratified patient subgroups and advances tailored treatment options for ASD. A first clinically and biologically defined subgroup of ASD patients, named ASD-Phen1, was clinically validated in 2 prospectives biosampling studies (Greenwood Genetic Center, Cincinnati Children’s Medical Center) with an observed incidence of 20-25% of the enrolled ASD population (Perez-Cano, et al. 2024). This subgroup was then biologically validated through multi-omics characterization (metabolic, metabolomic, transcriptomic) revealing specific molecular signatures for ASD-Phen1 patients that were found to be reversed by STALICLA's precision medicine STP1 (a combination of a PDE4/3 inhibitor (ibudilast) and an NKCC1 antagonist (bumetanide)). Ensuing STP1 Phase 1b in ASD-Phen1 established good safety-tolerability, strong target engagement signals (EEG), and superiority on recognized-clinical efficacy endpoints (ABC, SRS, NIH toolbox) as well as convincing PK/PD profile (Erickson, et al. 2024). <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e107"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e108"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e109"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e110"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d1771143e111"/>

Discovery Centre (CA)
Openalex Percentile: Top 78%
Autism Spectrum Disorder Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.